191 related articles for article (PubMed ID: 8958178)
1. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.
Merriman RL; Hertel LW; Schultz RM; Houghton PJ; Houghton JA; Rutherford PG; Tanzer LR; Boder GB; Grindey GB
Invest New Drugs; 1996; 14(3):243-7. PubMed ID: 8958178
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Csoka K; Liliemark J; Larsson R; Nygren P
Semin Oncol; 1995 Aug; 22(4 Suppl 11):47-53. PubMed ID: 7481845
[TBL] [Abstract][Full Text] [Related]
3. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
4. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
5. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.
Schultz RM; Merriman RL; Toth JE; Zimmermann JE; Hertel LW; Andis SL; Dudley DE; Rutherford PG; Tanzer LR; Grindey GB
Oncol Res; 1993; 5(6-7):223-8. PubMed ID: 8123942
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
10. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
11. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
13. [New antitumor antimetabolites--gemcitabine and DMDC].
Matsui K; Fukuoka M
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2127-32. PubMed ID: 1332622
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Wang H; Li M; Rinehart JJ; Zhang R
Clin Cancer Res; 2004 Mar; 10(5):1633-44. PubMed ID: 15014014
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Braakhuis BJ; Ruiz van Haperen VW; Boven E; Veerman G; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):42-6. PubMed ID: 7481844
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
18. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
19. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Pham NA; Tsao MS; Cao P; Hedley DW
Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
